Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease.
Bradner JE, Mak R, Tanguturi SK, Mazitschek R, Haggarty SJ, Ross K, Chang CY, Bosco J, West N, Morse E, et al. Proc Natl Acad Sci U S A. 2010 Jul 13; 107(28):12617-22. Epub 2010 Jun 28.